Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of Real-World Data for the Research, Development, and Evaluation of Oncology Precision Medicines
Jan Lewis, Ian Kerridge, Wendy Lipworth
JCO Precision Oncology (2017), Iss. 1, pp. 1-11
Open Access | Times Cited: 20

Showing 20 citing articles:

From hype to reality: data science enabling personalized medicine
Holger Fröhlich, Rudi Balling, Niko Beerenwinkel, et al.
BMC Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 368
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
Ruggero De Maria Marchiano, Gabriele Di Sante, Geny Piro, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 3, pp. 216-216
Open Access | Times Cited: 79
Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development
Timothy A. Yap, Ira Jacobs, Elodie Baumfeld Andre, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 30
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
Anika Kästner, Anna Kron, Neeltje van den Berg, et al.
The Lancet Regional Health - Europe (2023) Vol. 36, pp. 100788-100788
Open Access | Times Cited: 16
The Ethical Aspects of Exposome Research: A Systematic Review
Caspar Willem Safarlou, Karin Jongsma, Roel Vermeulen, et al.
Exposome (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 12
An Inflection Point in Cancer Protein Biomarkers: What was and What's Next
Anna D. Barker, Mario Alba, Parag Mallick, et al.
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 7, pp. 100569-100569
Open Access | Times Cited: 11
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, et al.
Haematologica (2018) Vol. 104, Iss. 4, pp. 797-804
Open Access | Times Cited: 33
Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics
Ani John, Roma Shah, William B. Wong, et al.
The Oncologist (2020) Vol. 25, Iss. 11, pp. e1743-e1752
Open Access | Times Cited: 29
Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’
C. Benedikt Westphalen, Carsten Bokemeyer, Reinhard Büttner, et al.
European Journal of Cancer (2020) Vol. 135, pp. 1-7
Closed Access | Times Cited: 28
Integrating Public Participation, Transparency and Accountability Into Governance of Marketing Authorisation for Genome Editing Products
Jane Nielsen, Lisa Eckstein, Dianne Nicol, et al.
Frontiers in Political Science (2021) Vol. 3
Open Access | Times Cited: 19
An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry
Christophe Le Tourneau, Camille Perret, Allan Hackshaw, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 9
Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients
Agnes Mattsson, Sandra Eketorp Sylvan, Anna Asklid, et al.
British Journal of Haematology (2020) Vol. 191, Iss. 3, pp. 426-432
Open Access | Times Cited: 8
External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations
Patrick Silva, Nora A. Janjan, Kenneth S. Ramos, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Overview of approaches to estimate real-world disease progression in lung cancer
Rossybelle P. Amorrortu, Melany A. Garcia, Yayi Zhao, et al.
JNCI Cancer Spectrum (2023) Vol. 7, Iss. 6
Open Access | Times Cited: 2
Digitale Medizin in der Onkologie: Clinical Decision Support, Real World Data und Patient Involvement
Sebastian Wagner, Hubert Serve
DMW - Deutsche Medizinische Wochenschrift (2019) Vol. 144, Iss. 07, pp. 430-434
Closed Access | Times Cited: 5
Molecular and modular intricacies of precision oncology
Ravneet Chhabra
Frontiers in Immunology (2024) Vol. 15
Open Access
Weighing false hope in population anticancer drug decision making
Charlotte Chamberlain, Richard Sullivan
Annals of Oncology (2018) Vol. 30, Iss. 1, pp. 10-11
Open Access | Times Cited: 3
Momentous Innovations in the Prospective Method of Drug Development
S. Jafar Ali Ibrahim, M. Thangamani
(2018), pp. 37-41
Closed Access | Times Cited: 2
A Network Approach to Developing Immuno-Oncology Combinations in Canada
Valerie Higenell, Richard Fajzel, Gerald Batist, et al.
Current Oncology (2019) Vol. 26, Iss. 2, pp. 73-79
Open Access | Times Cited: 1
Predicting therapeutic outcomes in Rheumatoid Arthritis using real-world pharmacogenetic and clinical data
Fabian Hernandez, Luís Fernando Niño, Fabio Aristizábal
2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) (2020), pp. 426-431
Closed Access
Page 1

Scroll to top